Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05069935 · ClinicalTrials.gov registry record · Phase 1
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
A Phase 1 study, sponsored by Fate Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT05069935: Clinical Trial Phase 1 study, sponsored by Fate Therapeutics.
NCT05069935 is a Phase 1 study that was terminated before completion, run by Fate Therapeutics. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05069935, a Phase 1 study, was terminated before completion, sponsored by Fate Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
Primary Outcome
To define the RP2D of FT538 in combination with the following mAbs in subjects with advanced solid tumors: avelumab, trastuzumab, cetuximab, atezolizumab, nivolumab, and pembrolizumab
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG FT538
- COMBINATION_PRODUCT Monoclonal antibody - Dose Escalation
- COMBINATION_PRODUCT Monoclonal antibody - Dose Expansion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-10-15 |
| Est. Completion | 2023-08-11 |
| Phase | Phase 1 |
Why NCT05069935 stopped before completion
NCT05069935 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT05069935 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05069935 about?
NCT05069935 is a clinical study titled "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors". This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
What is the current status of trial NCT05069935?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2021-10-15. Estimated completion is 2023-08-11.
What interventions are being tested in trial NCT05069935?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), FT538 (DRUG), Monoclonal antibody - Dose Escalation (COMBINATION_PRODUCT), Monoclonal antibody - Dose Expansion (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05069935?
This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05069935's enrollment target sits among peer trials
16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI